Expression of Keratin-1 Predicts Recurrence and Treatment Response in Advanced Laryngeal Cancer: A Potential Therapeutic Target.

IF 3.4 4区医学 Q2 ONCOLOGY

Current oncology Pub Date : 2025-09-17 DOI:10.3390/curroncol32090520

Eun Kyung Jung, S M Abdus Salam, Hye-Bin Jang, Joo Yeon Koo, Eshrat Jahan, Sun-Ae Kim, Ji Young Lee, Kyung-Hwa Lee, Tae Mi Yoon

{"title":"Expression of Keratin-1 Predicts Recurrence and Treatment Response in Advanced Laryngeal Cancer: A Potential Therapeutic Target.","authors":"Eun Kyung Jung, S M Abdus Salam, Hye-Bin Jang, Joo Yeon Koo, Eshrat Jahan, Sun-Ae Kim, Ji Young Lee, Kyung-Hwa Lee, Tae Mi Yoon","doi":"10.3390/curroncol32090520","DOIUrl":null,"url":null,"abstract":"<p><p>The survival rate of patients with advanced laryngeal cancer has not substantially improved over time. RNA sequencing analysis identified Keratin-1 (KRT1) as a gene potentially associated with cancer recurrence. This study investigated the association between KRT1 expression and recurrence in advanced laryngeal cancer. RNA sequencing was performed to identify candidate genes associated with recurrence. The effects of KRT1 expression on clinical outcomes were evaluated in patients with laryngeal cancer. Multiple experimental techniques were utilized. RNA sequencing of patient samples demonstrated higher KRT1 gene expression in the recurrence group than in non-recurrent cases. Patients with KRT1-positive immunostaining exhibited trends of worse overall survival (OS) and recurrence-free survival (RFS). In vitro studies showed that KRT1 knockdown suppressed tumor cell invasion, cell migration, and expression of epithelial-mesenchymal transition (EMT)-related genes in human head and neck squamous cell carcinoma (HNSCC) cell lines. KRT1 knockdown enhanced tumor cell apoptosis and exhibited synergistic effects with conventional radiation and chemotherapy treatments. KRT1 may serve as a biomarker for predicting advanced laryngeal cancer recurrence and assist with selecting patients to receive concurrent chemoradiotherapy (CCRT). Further molecular investigations are warranted to determine its effects, but KRT1 has potential as a therapeutic target.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468875/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/curroncol32090520","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The survival rate of patients with advanced laryngeal cancer has not substantially improved over time. RNA sequencing analysis identified Keratin-1 (KRT1) as a gene potentially associated with cancer recurrence. This study investigated the association between KRT1 expression and recurrence in advanced laryngeal cancer. RNA sequencing was performed to identify candidate genes associated with recurrence. The effects of KRT1 expression on clinical outcomes were evaluated in patients with laryngeal cancer. Multiple experimental techniques were utilized. RNA sequencing of patient samples demonstrated higher KRT1 gene expression in the recurrence group than in non-recurrent cases. Patients with KRT1-positive immunostaining exhibited trends of worse overall survival (OS) and recurrence-free survival (RFS). In vitro studies showed that KRT1 knockdown suppressed tumor cell invasion, cell migration, and expression of epithelial-mesenchymal transition (EMT)-related genes in human head and neck squamous cell carcinoma (HNSCC) cell lines. KRT1 knockdown enhanced tumor cell apoptosis and exhibited synergistic effects with conventional radiation and chemotherapy treatments. KRT1 may serve as a biomarker for predicting advanced laryngeal cancer recurrence and assist with selecting patients to receive concurrent chemoradiotherapy (CCRT). Further molecular investigations are warranted to determine its effects, but KRT1 has potential as a therapeutic target.

查看原文本刊更多论文

角蛋白1的表达预测晚期喉癌的复发和治疗反应：一个潜在的治疗靶点。

随着时间的推移，晚期喉癌患者的生存率并没有显著提高。RNA测序分析发现角蛋白-1 （KRT1）是一个与癌症复发潜在相关的基因。本研究探讨了KRT1表达与晚期喉癌复发的关系。进行RNA测序以确定与复发相关的候选基因。评估KRT1表达对喉癌患者临床预后的影响。采用多种实验技术。患者样本的RNA测序显示，复发组的KRT1基因表达高于非复发组。krt1免疫染色阳性的患者表现出更差的总生存期（OS）和无复发生存期（RFS）的趋势。体外研究表明，KRT1敲低可抑制人头颈部鳞状细胞癌（HNSCC）细胞系中肿瘤细胞的侵袭、细胞迁移以及上皮-间质转化（EMT）相关基因的表达。KRT1敲低可增强肿瘤细胞凋亡，并与常规放化疗具有协同作用。KRT1可以作为预测晚期喉癌复发的生物标志物，并帮助选择接受同步放化疗（CCRT）的患者。需要进一步的分子研究来确定其作用，但KRT1具有作为治疗靶点的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current oncology ONCOLOGY-

CiteScore

3.30

自引率

7.70%

发文量

664

审稿时长

1 months

期刊介绍： Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease. We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.